Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech and AstraZeneca Sign New Three-Year Collaboration

publication date: Jun 10, 2008

WuXi PharmaTech has extended its collaboration with AstraZeneca for an additional three years. The first collaboration between the two companies, a $14 million two-year agreement begun in 2006, was very successful. During the last two years, using its high throughput screening capability, WuXi delivered over 100,000 compounds to AstraZeneca, two months ahead of schedule. The new agreement calls for WuXi to, once again, synthesize compounds, following designs indicated by AstraZeneca. More details...

Stock Symbols: (NYSE: WX) (NYSE: AZN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here